US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Summit Therapeutics Inc.
< Previous
1
2
Next >
Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
June 30, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
RVMD
SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
June 05, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study
May 30, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 16, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025
May 01, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China
April 25, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025
April 24, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China
April 23, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 21, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer
March 17, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 14, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024
February 24, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)
February 24, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025
February 18, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 14, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 07, 2025
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 13, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics to Present at Upcoming Investor Conferences
November 26, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 21, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024
October 30, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics to Host Third Quarter 2024 Financial Results & Operational Progress Call on October 30, 2024
October 23, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC
October 03, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
September 16, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Raises $235 Million
September 12, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China
September 08, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
HARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024
August 12, 2024
From
Summit Therapeutics Inc.
Via
Business Wire
Tickers
SMMT
< Previous
1
2
Next >
